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Abstract
Background
Loss to care is high among asymptomatic HIV-infected women initiated on antiretroviral
therapy (ART) during pregnancy or in the postpartum period. However, whether pregnancy
itself plays a role in the high loss to care rate is uncertain. We compared loss to care over
seven years between pregnant and non-pregnant women at enrollment into HIV care in the
Democratic Republic of Congo (DRC).

Methods
We conducted a retrospective analysis of all ART-naive women aged 15–45 initiating HIV
care at two large clinics in Kinshasa, DRC, from 2007–2013. Pregnancy status was
recorded at care enrollment. Patients were classified as having no follow-up if they did not
return to care after the initial enrollment visit. Among those with at least one follow-up visit
after enrollment, we classified patients as lost to care if more than 365 days had passed
since their last clinic visit. We used logistic regression to model the association between
pregnancy status and no follow-up, and Cox proportional hazards regression to model the
association between pregnancy status and time to loss to care.

Results
Of 2175 women included in the analysis, 1497 (68.8%) were pregnant at enrollment. Compared to non-pregnant women, pregnant women were less likely to be over 35 years of age

PLOS ONE | https://doi.org/10.1371/journal.pone.0195231 April 2, 2018

1 / 13

Loss to HIV care in DRC by pregnancy status

Their study team had access to a larger data set
from which the minimal data set was derived.
Thus, they had the ability to cross-check certain
variables against other data. All analyses were
conducted using the minimal dataset that will be
available to researchers making a request to access
it.
Funding: This study was conducted as part of the
Central Africa International Epidemiologic
Databases to Evaluate AIDS (CA-IeDEA)
consortium, which is funded by the National
Institute of Allergy and Infectious Diseases (https://
www.niaid.nih.gov, grant number U01 AI096299 to
KA), and received additional support from the
Eunice Kennedy Shriver National Institute of Child
Health and Human Development (https://www.
nichd.nih.gov, grant number R01 HD087993) and
National Institute of Mental Health grant K23
MH114752 to JR. The funders had no role in study
design, data collection and analysis, decision to
publish, or preparation of the manuscript.
Competing interests: The authors have declared
that no competing interests exist.

(19.1% vs. 31.9%, p<0.0001) and less likely to be in WHO stage III or IV (9.0% vs. 26.3%,
p<0.0001). Among pregnant women, 106 (7.1%) were not seen after enrollment, versus 25
(3.7%) non-pregnant women (adjusted odds ratio 2.01, 95% CI 1.24–3.24). Of the 2,044
women with at least one follow-up visit, 46.5% of pregnant women and 46.7% of non-pregnant women were lost to care by 5 years; hazards of loss to care were similar for pregnant
and non-pregnant women (adjusted hazard ratio 1.08, 95% CI 0.93–1.26).

Conclusions
In this large cohort of HIV-infected women, patients pregnant at care enrollment were more
likely to never return for follow-up. Among those who attended at least one follow-up visit,
loss to care was not different between pregnant and non-pregnant women, suggesting that
pregnancy itself may not be the main driver of the high attrition observed in this cohort.

Introduction
Of 1.4 million pregnant women living with HIV globally, over 90% reside in sub-Saharan
Africa [1, 2]. Without any intervention, 20−45% of pregnant women will transmit HIV to their
infants during pregnancy, labor/delivery, or breastfeeding [3]. Antiretroviral therapy (ART)
use during pregnancy and breastfeeding dramatically reduces mother-to-child HIV transmission and improves women and infant outcomes [4, 5]. The past decade has seen enormous
scale up of prevention of mother-to-child HIV transmission (PMTCT) services in sub-Saharan
Africa, including ART access [6]. However, suboptimal retention of pregnant women along
the PMTCT cascade exists, with up to 48% of women not retained through 6 months postdelivery [7–9]. Under World Health Organization (WHO) guidelines recommending lifelong
combination ART for all pregnant and breastfeeding HIV infected women, referred to as
Option B+ [10], about a sixth of pregnant women initiating ART do not return for a follow-up
visit and overall loss to care of women initiating HIV care when pregnant remains high [11–
13].
Uncertainty exists about factors driving high loss to care among pregnant women initiating
HIV care. Compared to non-pregnant women, pregnant women initiating HIV care are younger and have less advanced HIV disease [14], factors that have been associated with poor retention [15, 16]. After adjusting for these characteristics, multiple large investigations still
reported greater loss to care among pregnant women [11–13, 17]. However, interpreting these
findings is difficult as different ART eligibility criteria exist for pregnant and non-pregnant
women in these studies. Few studies have compared retention in care of pregnant and nonpregnant women before implementation of the 2013 WHO guidelines; those investigations
only included patients initiating ART. It is therefore unclear whether the high loss to care
observed among pregnant versus non-pregnant women in these studies resulted from lack of
patient readiness to start ART, or factors secondary to pregnancy itself.
Most sub-Saharan Africa nations have already adopted Option B+, and nearly all are beginning to provide ART to all people living with HIV regardless of CD4 count. Understanding
whether pregnancy at care enrollment is a main predictor of the loss to care observed following
the implementation of Option B+ is essential to developing and targeting interventions aimed
at maintaining the broader population of people living with HIV in care. This study’s goal was
thus to compare loss to HIV care by pregnancy status at enrollment at two sites in the Democratic Republic of Congo (DRC) from 2007–2013, a period prior to implementation of lifelong
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ART for pregnant and breastfeeding women living with HIV. We hypothesized that women
who were pregnant at enrollment would have increased loss to care compared to women who
were not pregnant.

Methods
We performed a retrospective cohort study of women living with HIV enrolling in HIV care
from 2007–2013 at two sites in Kinshasa, DRC that are affiliated with the Central Africa International Epidemiologic Databases to Evaluate AIDS (CA-IeDEA) Consortium. CA-IeDEA is a
multi-country project that collects secondary data from patients receiving HIV care and treatment in the Central African region. Patient data from sites participating in CA-IeDEA are deidentified at the clinic level prior to entry in the cohort database. All research was conducted
according to the principles of the Declaration of Helsinki and approved by the Kinshasa School
of Public Health Ethics Committee and the Institutional Review Board of the Albert Einstein
College of Medicine, both of which waived written or verbal patient consent because the data
were de-identified prior to analysis.

Setting
Data were collected at two comprehensive HIV care programs serving patients at Kalembelembe Pediatric Hospital (KLL) and Bomoi Healthcare Center (BHC) in Kinshasa, DRC [18,
19]. The DRC is a large, Central African country with a population of over 80 million and an
overall HIV prevalence of 0.8% [20]. An estimated 200,000 Congolese women aged 15–49 are
HIV-infected. Up to 15% of pregnancies among HIV-infected women result in HIV transmission to infants [20]. From 2013 Demographic and Health Surveys in DRC [21], roughly 9 in 10
mothers in DRC and 96% in Kinshasa attended at least one antenatal care visit before their
most recent delivery. Breastfeeding is virtually universal in DRC; 9 out of 10 infants still breastfeed at 1 year [22, 23]. From its origins in the early 2000s until 2010, the DRC PMTCT program was based on provision of a single intra-partum dose of nevirapine, with the addition of
daily AZT/3TC until 7 days postpartum recommended starting in 2006 [24, 25]. Option A–the
provision of zidovudine starting as early as 14 weeks through delivery for women ineligible for
ART [26]–was introduced in 2009 and fully implemented in DRC by 2010; this remained the
standard of care until the implementation of Option B+ in 2015.

Population and clinical procedure
We included all ART-naïve women aged 15–45 years who enrolled in HIV care from January
1, 2007 through July 31, 2013. Women were diagnosed with HIV at the two sites or referred to
these sites from affiliated PMTCT sites. Patients enrolled into HIV care at their first post-diagnosis visit at KLL or BHC. At this visit, data were collected on pregnancy status, weight, age,
WHO clinical stage, and CD4 count. Decisions to start ART were based on WHO clinical
stage (III or IV), CD4 count (200 cells/mm3 prior to 2010 or 350 cells/mm3 after 2010) or
provider discretion. Pregnant women ineligible for ART received either a single intrapartum
dose of nevirapine with or without daily AZT/3TC until 7 days postpartum (from 2007–2009),
or a regimen of zidovudine during pregnancy (2010–2013) and were considered not to have
used ART. Scheduled follow-up differed by calendar period and whether or not patients had
initiated ART. From 2007–2009, patients on ART were typically scheduled for monthly visits,
and patients not on ART were typically seen quarterly. In subsequent years, patients on ART
were initially seen monthly, but once stable on ART were scheduled quarterly; those not on
ART were seen biannually. Though tracking practices were not uniform throughout the study
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period, typically, for patients who did not attend scheduled visits, up to three phone contacts
were attempted, followed by a home visit.

Outcomes and predictor variables
Two primary outcomes were considered in this analysis: no follow-up and loss to care. Patients
were classified as having no follow-up if they did not return to care after the initial enrollment
visit, and were not included in analyses of loss to care. We defined loss to care as an interval of
more than 365 days since last clinic visit to avoid misclassification among patients scheduled
for infrequent (biannual) visits. In a sensitivity analysis, we also examined loss to care using a
definition of 182 days since last clinic visit. Other covariates included: ART initiation within
three months of enrollment (yes or no); pregnancy status; baseline age (categorized as 15–24,
25–34, or 35–45 years at enrollment); baseline CD4 count (classified as <200, 201–350, or
>350 cells/mm3); and WHO clinical stage (I or II, III or IV, missing) each of these obtained at
any visit up to 30 days after enrollment.

Statistical analyses
Baseline characteristics of pregnant and non-pregnant women were compared using chisquare tests for categorical and Mann-Whitney tests for continuous variables. For the outcome
of no follow-up, we used bivariate and multivariable logistic regression models respectively to
generate crude and adjusted odds ratios (ORs) with 95% confidence intervals (CIs) comparing
proportions of women with no follow-up after enrollment by pregnancy status at enrollment.
For those who returned for at least one post-enrollment visit, Kaplan-Meier survival analyses
were used to compare proportions of pregnant and non-pregnant women lost to care over follow-up time. We then used Cox proportional hazard models to generate hazard ratios (HRs)
with 95% CIs comparing loss to care by pregnancy status at enrollment. For these analyses,
patients were censored at the date of their last clinic visit (if they had one of the following
events: lost to care, died, or transferred clinics) or 365 days before the database closing date of
August 1, 2013 (if they did not have an event). We also conducted a sensitivity analysis exploring whether the association between pregnancy status at enrollment and loss to care differed
when limiting follow-up time to the first 2 years after enrollment, when pregnancy might be
expected to have the strongest effect. For this analysis, we utilized a 182-day loss to care definition and censored patients who did not have an event by 24 months after their enrollment
date. Data were analyzed using SAS 9.3 (SAS Institute Inc., Cary, NC). Statistical significance
was two-sided at p<0.05.

Results
Of the 2175 women enrolled in care at the two clinics from 2007 through 2013, 982 (45.1%)
enrolled from 2007–2009 and 1173 (54.9%) from 2010–2013. At enrollment, 1497 (68.8%)
were pregnant, median age was 30 years (interquartile range [IQR] 26–34), and 312 (14.3%)
were in WHO clinical stage III or IV (Table 1). Median CD4 count at enrollment was 356
cells/mm3 (IQR 215–534). A total of 131 patients (6.0%) did not return after the enrollment
visit.
Compared to non-pregnant women, pregnant women at enrollment were less likely to: be
over 35 years of age (19.1% vs. 31.9%, p<0.0001), enroll in care during 2010–2013 compared
to 2007–2009 (49.7% vs. 68.4%, p<0.0001), and be in WHO clinical stage III or IV (9.0% vs.
26.3%, p<0.0001). Notably, baseline CD4 counts did not statistically differ between the two
groups (p = 0.31).
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Table 1. Baseline demographic and clinical characteristics of HIV-infected women who received care at Kalembelembe Pediatric Hospital and Bomoi Healthcare
Center in Kinshasa, DRC, 2007–2013 (N = 2175).
Characteristic

Total (n = 2175)

Pregnant (n = 1497)

Not pregnant (n = 678)

P
<0.0001^

Year of enrollment, n (%)
2007–2009

982 (45.1)

768 (51.3)

214 (31.6)

2010–2013

1193 (54.9)

729 (49.7)

464 (68.4)
<0.0001^

Age, n (%)
15–24

372 (17.1)

273 (18.2)

99 (14.6)

25–34

1301 (59.8)

938 (62.7)

363 (53.5)

35–45

502 (23.1)

286 (19.1)

216 (31.9)
<0.0001^

WHO clinical stage, n (%)
Stage I or II

1848 (85.0)

1351 (90.2)

497 (73.3)

Stage III or IV

312 (14.3)

134 (9.0)

178 (26.3)

15 (0.7)

12 (0.8)

3 (0.4)

356 (215–534)

349 (224–515)

366 (196–574)

0.31&

802 (36.9)

506 (33.8)

296 (43.7)

<0.0001^

4 (3–6)

4 (3–5)

5 (3–6)

<0.0001&

No follow-up after enrollment, n (%)

131 (6.0)

106 (7.1)

25 (3.7)

<0.0001^



860 (42.1)

572 (41.0)

288 (43.8)

0.60^

Transferred to another facility

32 (1.5)

21 (1.4)

11 (1.6)

0.69^

Died

91 (4.2)

56 (3.7)

35 (5.2)

0.13^

Missing
CD4 count, median cells/mm3 (IQR)
ART initiated within 3 months of enrollment, n (%)
Median years of follow-up (IQR)
Lost to care, n (%)

DRC = Democratic Republic of Congo.
IQR = interquartile range.
WHO = World Health Organization.
ART = antiretroviral therapy.
^ represents probability of observed result using chi-squared test of independence.
&



represents probability of observed result using Wilcoxon Rank-Sum test.
denominators do not include the 131 women (106 pregnant and 25 not pregnant) who did not return after the enrollment visit.

https://doi.org/10.1371/journal.pone.0195231.t001

Among 2,044 patients who returned for at least one visit after enrollment, 865 (42.3%) were
eligible for ART at enrollment based on CD4 count and/or WHO stage, of whom 660 (76.3%)
started ART within 3 months (Fig 1). An additional 142 patients initiated ART within 3 months
of enrollment, and another 465 patients initiated ART beyond 3 months. In total, 1267 patients
(58.3%) initiated ART during the follow-up period. Among patients meeting CD4 and/or WHO
stage criteria for ART initiation, similar proportions of pregnant and non-pregnant women initiated ART within three months after enrollment into care (75.0% vs 78.6%, p = 0.23).

No follow-up
Of 1497 pregnant women enrolled in HIV care, 106 (7.1%) were not seen after enrollment,
compared to 25 (3.7%) of 678 non-pregnant women (OR comparing pregnant to non-pregnant women 1.99, 95% CI 1.27–3.11), p<0.01). In logistic regression analysis adjusted for year
of enrollment, age at enrollment, baseline CD4 count, and WHO clinical stage, pregnant
women were about twice as likely not to be seen after enrollment (adjusted OR 2.11, 95% CI
1.24–3.24) (Table 2).

Loss to care
We included the 2044 women who returned for at least one post-enrollment visit in the analysis of loss to care (Fig 2). Median follow-up time among those patients was 4.5 years (IQR 3.0–
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Fig 1. Flow chart describing study population.
https://doi.org/10.1371/journal.pone.0195231.g001

5.8), and cumulative proportions of pregnant and non-pregnant patients lost to care at 1, 2, 3,
4 and 5 years after enrollment were as follows: for pregnant patients, 23.1% (95% CI 20.9–
25.4%), 32.3% (95% CI 29.9–35.0%), 37.9% (95% CI 35.3–40.7%), 41.8% (95%CI 39.1–44.6%),
and 46.5% (95%CI 43.5–49.7%); for non-pregnant patients, 19.2% (95%CI 16.3–22.5%), 28.5%
(95% CI 25.1–32.3%), 36.3% (95%CI 32.5–40.4%), 41.1% (95% CI 37.1–45.4%), and 46.7%
(95% CI 42.4–51.2%), respectively. In bivariate analysis, loss to care did not differ significantly
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Table 2. Associations of demographic and clinical characteristics at enrollment and having no follow-up after enrollment (N = 2175).
No follow-up (n = 131)

Characteristic

Followed-up (n = 2044)

Crude OR (95% CI)

Adjusted OR (95% CI)

Pregnant
No

25 (3.7)

653 (96.3)

Ref.

Ref.

Yes

106 (7.1)

1391 (92.9)

1.99 (1.27, 3.11)

2.01 (1.24, 3.24)

Age (years)
15–24

36 (9.7)

336 (90.3)

Ref.

Ref.

25–34

76 (5.8)

1225 (94.2)

0.58 (0.38, 0.88)

0.65 (0.42, 1.01)

19 (3.8)

483 (96.2)

0.37 (0.21, 0.65)

0.45 (0.25, 0.83)

< 200

13 (2.9)

433 (97.1)

Ref.

Ref.

200–350

23 (4.3)

516 (95.7)

1.48 (0.74, 2.97)

1.32 (0.65, 2.67)

> 350

62 (6.1)

958 (93.9)

2.16 (1.17, 3.96)

1.89 (1.01, 3.53)

Missing

33 (19.4)

137 (80.6)

8.02 (4.11, 15.70)

7.62 (3.83, 15.20)

I

87 (6.3)

1302 (93.7)

Ref.

Ref.

II

26 (5.7)

433 (94.3)

0.90 (0.57, 1.41)

1.00 (0.63, 1.60)

35–45
3

CD4 count (cells/mm )

WHO clinical stage

III

9 (3.6)

243 (96.4)

0.55 (0.28, 1.12)

0.85 (0.41, 1.76)

IV

3 (5.0)

57 (95.0)

0.79 (0.24, 2.57)

0.81 (0.24, 2.77)

Missing

6 (40.0)

9 (60.0)

9.98 (3.47, 28.70)

7.84 (2.52, 24.40)

Year of enrollment
2007–2009

64 (6.5)

918 (93.5)

Ref.

Ref.

2010–2013

67 (5.6)

1126 (94.4)

0.85 (0.60, 1.22)

0.93 (0.64, 1.34)

OR = odds ratio.
CI = confidence interval.
WHO = World Health Organization.
Ref = referent category.


Patients were classified as having no follow-up if they did not return to care after the initial enrollment visit and otherwise were classified as followed-up.

https://doi.org/10.1371/journal.pone.0195231.t002

between pregnant and non-pregnant women (HR 1.04, 95% CI 0.90–1.20; p = 0.6 for log-rank
test). When adjusted for baseline characteristics and starting ART within three months after
enrollment, hazards of loss to care remained similar for the two groups (adjusted HR for pregnant women versus non-pregnant women 1.08, 95% CI 0.93–1.26) (Table 3). Sensitivity analyses using a 182-day definition for loss to care demonstrated similar results for the entire
follow-up period (aHR 1.09, 95% CI 0.95–1.25) as well as when follow-up time was limited to
24 months after enrollment (aHR 1.19, 95% CI 0.99–1.43).

Discussion
This analysis of loss to HIV care of Congolese women found that those pregnant at care enrollment were more likely to never return for follow-up. However, among those who attended at
least one follow-up visit, there were no statistically significant differences in loss to care by
enrollment pregnancy status. This suggests that further efforts to retain women diagnosed
with HIV in pregnancy should focus at the earliest point in care delivery, and that once pregnant women are established in care they can be retained in care as well as non-pregnant
women.
About 6% of women who enrolled into care never returned for a follow-up visit. This was
about twice as likely to occur among pregnant women versus non-pregnant women. Our
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Fig 2. Kaplan-Meier curves for time to loss to care among those who returned for at least one post-enrollment visit, by pregnancy status at
enrollment (N = 2044). Includes participants who had  1 follow-up visit after enrollment. Pregnancy status was recorded at enrollment into care.
Participants were classified as lost to care (on their last clinic visit) if > 365 days had passed since their last clinic visit. All participants who did not
experience the outcome were censored at the date of last clinic visit or when they were no longer at risk for loss to care (365 days before the database
closing date).
https://doi.org/10.1371/journal.pone.0195231.g002

results are similar to other studies undertaken both prior to and after implementation of Option
B+, which found that pregnant women are two to five times more likely to never return after
enrollment into care [11–13, 27]. Many women diagnosed with HIV during routine prenatal
screening may be overwhelmed by needing to simultaneously process their diagnosis and deal
with competing demands of pregnancy [28–30]. Notably, the proportion of women who never
returned for a follow-up visit in our study was substantially lower than these other cohorts [11–
13, 27], where 20–33% of patients did not return after the enrollment visit. This finding may be
due to the fact that most women in our study were referred to the HIV care and treatment sites
from affiliated clinics. It is possible that a substantial proportion of HIV infected women referred
to those clinics were lost to care prior to the enrollment visit by never acting on the referral.
Among women who attended at least one follow-up visit, we found no difference in the
hazards of loss to care between pregnant and non-pregnant women, before and after adjusting
for baseline differences between these groups. This result differs somewhat from those
reported by Haas, et al [12]. In that study, among pregnant and non-pregnant women attending at least one follow-up visit after enrollment, pregnant women had lower odds of retention
at years 1 and 2 after enrollment versus non-pregnant women, a difference that was no longer
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Table 3. Associations of demographic and clinical characteristics at enrollment and loss to care among HIV-infected women with at least one visit after enrollment
in care (N = 2044).
Characteristic

Crude HR (95% CI)



Lost to care (n = 860)

Not lost to care (n = 1184)

No

288 (44.1)

365 (55.9)

Ref.

Ref.

Yes

572 (41.1)

819 (58.9)

1.04 (0.90, 1.20)

1.08 (0.93, 1.26)

15–24

176 (52.4)

160 (47.6)

Ref.

Ref.

25–34

521 (42.5)

704 (57.5)

0.72 (0.60, 0.85)

0.76 (0.64, 0.90)

35–45

163 (33.8)

320 (66.3)

0.52 (0.42, 0.65)

0.57 (0.46, 0.71)

< 200

145 (33.5)

288 (66.5)

Ref.

Ref.

200–350

194 (37.6)

322 (62.4)

1.10 (0.89, 1.36)

1.08 (0.87, 1.34)

> 350

446 (46.6)

512 (53.4)

1.39 (1.15, 1.67)

1.31 (1.08, 1.58)

Missing

75 (54.8)

62 (45.3)

1.99 (1.50, 2.63)

2.05 (1.54, 2.72)

Adjusted HR (95% CI)

Pregnant

Age (years)

CD4 count (cells/mm3)

WHO clinical stage
I

574 (44.1)

728 (55.9)

Ref.

Ref.

II

176 (40.7)

257 (59.4)

0.89 (0.75, 1.05)

0.99 (0.83, 1.17)

III

86 (35.4)

157 (64.6)

0.77 (0.61, 0.97)

0.88 (0.70, 1.12)

IV

18 (31.6)

39 (68.4)

0.73 (0.45, 1.16)

0.76 (0.47, 1.22)

Missing

6 (66.7)

3 (33.3)

1.78 (0.80, 3.98)

1.32 (0.58, 2.99)

2007–2009

376 (41.0)

542 (59.0)

Ref.

Ref.

2010–2013

484 (43.0)

642 (57.0)

1.52 (1.32, 1.75)

1.56 (1.35, 1.80)

Year of enrollment

ART initiated within 3 months
No

607 (48.8)

637 (51.2)

Ref.

Ref.

Yes

253 (31.6)

547 (68.4)

0.60 (0.52, 0.69)

0.54 (0.44, 0.65)

HR = hazard ratio.
CI = confidence interval.
WHO = World Health Organization.
ART = antiretroviral therapy.
Ref = referent category.
HRs calculated from proportional hazards models of time to last clinic visit.



Includes participants who had  1 follow-up visit after enrollment. Pregnancy status was recorded at enrollment into care. Participants were classified as lost to care (on
their last clinic visit) if > 365 days had passed since their last clinic visit. All participants who did not experience the outcome were censored at the date of last clinic visit
or when they were no longer at risk for loss to care (365 days before the database closing date).
https://doi.org/10.1371/journal.pone.0195231.t003

significant at year 3 of follow-up. The study by Haas, et al compared pregnant women on
Option B+ (immediate ART initiation) to non-pregnant women initiating ART because they
met immunological criteria. It is possible that the stronger negative effect of pregnancy on
retention they reported resulted from differences between pregnant and non-pregnant women
with respect to time in care prior to ART initiation: pregnant women were eligible for immediate ART initiation, whereas women initiating ART because of meeting immunological criteria
typically needed to be in care at least long enough to be evaluated for ART eligibility. Other
studies that did not distinguish between patients with no follow-up and those who attended at
least one follow-up visit have also reported higher loss to follow-up among pregnant women
initiating ART compared to non-pregnant women [31–33]. Similar to the Haas et al. study, in
these studies, follow-up for non-pregnant women started at ART initiation, inducing a left-
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censoring bias (any loss to follow-up that occurred between enrollment and ART initiation
was not included in the analyses). Our analysis attempts to control for this bias by counting
follow-up time in both groups from enrollment and is more relevant to the current context of
test-and-treat in which all HIV-infected patients are expected to start ART immediately.
While few studies have described long-term loss to care of pregnant women in HIV care,
Haas et al. reported that over 30% of pregnant women were lost at three years after enrollment
[12]. Similarly, in our study, we observed that loss to care was high for both pregnant and nonpregnant women, with nearly half the cohort lost to follow-up at five years after enrollment.
We further observed that older age, more advanced HIV, and starting ART within three
months of enrollment were associated with a lower hazard of loss to follow-up, consistent with
findings from other studies [34–36]. Feeling healthy, stigma and anxiety about lifelong treatment are established barriers to retention in HIV care, and may explain these results [37, 38].
Among women enrolling in HIV care while pregnant, specific barriers to retention include
prioritizing children’s health over their own, non-disclosure to partners, HIV status denial,
and economic concerns [39–41]. While few other studies have examined long-term retention
in care of pregnant women, attrition of 30–50% of patients initiating care has been observed in
cohorts of general populations [42, 43], adolescents [44], and special populations in sub-Saharan Africa [45]. Although our results reflect the challenges of maintaining patients in longterm HIV care, our finding that patients who initiated ART within 3 months of care enrollment were nearly twice as likely to remain in care as those who did not suggests that early ART
initiation under universal test and treat may promote greater retention in care than observed
to date in sub-Saharan Africa.
This study has several limitations. The cohort consisted of patients from only two clinics in
a country with a relatively low prevalence and burden of HIV compared to other sub-Saharan
African countries, which may limit the generalizability of our findings. Additionally, we only
included women who enrolled in care in these clinics, but were unable to account for women
who were referred to the clinics and never enrolled. While some patients were known to have
died or transferred to other facilities, it is possible that additional patients unknowingly experienced these outcomes and were misclassified as lost to care. Because we analyzed previously
collected data, we were unable to examine additional factors (e.g., income, distance from
clinic) that may have influenced outcomes.

Conclusions
In this large cohort of women enrolled in HIV care in two clinics in Kinshasa, DRC, we found
similar rates of loss to care among pregnant and non-pregnant women. These results suggest
that pregnancy itself may not be the main driver of poor retention in HIV care but that confounding factors may also be responsible for the high attrition noted during the early implementation of universal treatment of pregnant women living with HIV under Option B+. As
universal test and treat is implemented across sub-Saharan Africa, special attention should be
paid to the problem of drop-out immediately following enrollment.
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